Hospitals track CLABSIs down to the decimal point.
They build dashboards. Launch task forces. Tie outcomes to reimbursement and reputation.
And yet, one of the most common causes of preventable patient harm in the hospital continues to happen quietly, inconsistently reported, and largely unmeasured.
Peripheral IV infiltrations and extravasations—PIVIEs—are the riskiest silent hospital-acquired events.
Not because they are rare, but because no one is required to document them.
The PIVIE Oversight Problem
Unlike CLABSIs, CAUTIs, or pressure injuries, there is no governing body mandating standardized reporting, tracking, or benchmarking for PIVIEs. No national definitions. No universal metrics. No financial penalties tied to outcomes.
If a PIVIE causes severe tissue injury, blistering, necrosis, or the need for surgical intervention, it may be documented—but it may never make it onto a quality dashboard. It may never be compared year over year. And it may never trigger a systemic response.
What isn’t measured isn’t managed. And what isn’t managed quietly continues.
The Unintended Consequence of CLABSI Reduction
In an effort to reduce CLABSIs, alongside other clinical considerations, many hospitals have evaluated their central line utilization policies and strengthened their criteria for both initial placement and ongoing use, leading to increased reliance on peripheral IV access.
But here is the paradox hospitals now face, they have shifted risk elsewhere.
Medications that were once delivered centrally are now being administered peripherally. Vesicants. Irritants. High-risk infusions. Often through short-dwell peripheral IVs on patients with fragile veins, edema, or limited vascular access.
This shift doesn’t eliminate risk—it redistributes it.
And while CLABSI harm is aggressively tracked and scrutinized, the harm from peripheral IV infiltrations and extravasations often go unnoticed until a visible injury appears.
Hospitals Are On Their Own.
Without external mandates, hospitals are left to individually decide:
- What constitutes a reportable PIVIE
- How to document severity
- Whether trends are reviewed
- And what level of injury is considered “acceptable”
That variability leaves facilities exposed. It leaves clinicians unsupported. And it leaves patients vulnerable to preventable harm.
Yes, PIVIEs Will Happen. Severe Harm Doesn’t Have To.
Let’s be clear: infiltrations and extravasations will happen, even in incredibly skilled hands. Peripheral IV therapy is not risk-free, but the most devastating outcomes—deep tissue injury, necrosis, long-term impairment—are not inevitable. They are the result of late detection.
By the time swelling and skin changes are visible, the damage is already done.
Early detection changes everything.
From Silent Harm to Visible Prevention
IV surveillance technology provides something policies and antidotes alone cannot: time.
Time to detect a problem before tissue injury occurs.
Time to intervene early, when a simple antidote may be sufficient.
Time to prevent serious harm rather than respond to it.
Until PIVIEs are systematically tracked and addressed with the same accountability applied to other hospital-acquired conditions, they will continue to cause preventable harm outside formal oversight.
Take Proactive Action
Mandates aren’t necessary for hospitals committed to reducing avoidable patient harm. Proactive organizations don’t wait for regulation to define the standard—they set it themselves. They establish multidisciplinary committees, consistently track and trend their PIVIEs, grade the severity of harm, and hold teams accountable for improvement. Most importantly, they implement IV surveillance technology like ivWatch to enable early detection and timely intervention. By creating structure, visibility, and real-time awareness around peripheral IV risk, these hospitals move PIVIEs out of the shadows and into a measurable, manageable patient safety strategy.
Learn more about technology.